Targeting the OX40 Pathway in Atopic Dermatitis: Lessons Learned From Recent Clinical Data

Drs. Bunick and Shahriari discuss the emerging role of the OX40/OX40L pathway in atopic dermatitis, highlighting how targeting antigen-specific T cells may rebalance the immune system and potentially induce durable, off-drug remission. They review promising phase 2 and 3 data for agents like rocatinlimab and amlitelimab, emphasize encouraging safety profiles, and explore future innovations such as combination and bispecific approaches to improve both speed and durability of disease control.